Business and Industry
Lucid News
2020-04-07
Challenges to a Company‚ Psilocybin Patent Highlight Contrasting Business Strategies for Developers of Psychedelic Therapies
Tactics used by Compass Pathways common to pharma companies pose ethical questions for the emerging psychedelics industry. Part one of a three-part series.
Share:
Related News
Psychedelic Science 2025: Set and (Re)Setting
For its fifth installment, Psychedelic Science 2025 returned to Denver, offering three days of big ideas, heartfelt community, and some noticeable shifts in the psychedelic space. After the usual chaos of delayed flights and travel drama on Tuesday, we shared a collective sigh of relief as we finally arrived at the Colorado Convention Center, a mile high and ready to dive in.
Read More
Mindstate Uses AI to Design “Next-Gen” Psychedelics Combined With 5-MeO-MiPT
Mindstate Design Labs has received approval for a Phase 1 clinical trial to investigate the use of its formulation of 5-MeO-MiPT which it hopes to combine with other drugs to target precise serotonin receptors and create future psychotropic therapies.
Read More
The Church of the Eagle and the Condor Settles with Federal Agencies, Can Continue Importing and Using Ayahuasca
Here, we explore the settlement as well as the potential repercussions for other religious groups that seek to use psychedelics as part of their practices. We also share a response from certain…
Read More